Skip to main content
. 2020 Jan 27;64(2):e01711-19. doi: 10.1128/AAC.01711-19

FIG 2.

FIG 2

Number of isolates susceptible, intermediate, and resistant to aminoglycosides, determined using CLSI, EUCAST, and FDA breakpoints, including all isolates studied. S, susceptible; I, CLSI intermediate and EUCAST susceptible increased exposure categories; R, resistant; PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin.